FDA Approves First Treatment for Sanfilippo Syndrome Type A
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Fayuvi, a one-time gene therapy from Ultragenyx Pharmaceutical Inc., as the first treatment for children with mucopolysaccharidosis type IIIA, providing …
FDA Approves First Treatment for Sanfilippo Syndrome Type A Read More